Navigation Links
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Date:5/21/2008

th moderate to severe Crohn's disease to study the safety and efficacy of HUMIRA in maintaining clinical remission up to 56 weeks. After week four, 778 patients were randomized to placebo, HUMIRA 40 mg every other week (EOW) or 40 mg weekly (EW) in blinded fashion. At or after week 12, patients with flares or non-responders could receive open-label 40 mg EOW and 40 mg EW for continued flare or nonresponse.

The co-primary endpoints evaluated the maintenance of clinical remission at weeks 26 and 56 for each HUMIRA group compared to those on placebo. A significantly greater percentage of patients treated with HUMIRA maintained clinical remission at one year compared to placebo.

About the GAIN Trial

In the GAIN (Gauging Adalimumab effectiveness in Infliximab Nonresponders) study, a four-week induction trial of 325 patients who lost response or were intolerant to infliximab, three times as many patients taking HUMIRA achieved clinical remission at week four versus placebo (21 percent versus 7 percent, respectively).

"HUMIRA's ability to effectively treat the chronic symptoms of Crohn's disease makes it an important option for gastroenterologists and patients looking for improved disease management," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott.

HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. HUMIRA is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.

The recommended HUMIRA dose regimen for adult patients with Crohn's disease is 160 mg initially at Day 1 (given as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days), followed by 80 mg two weeks later (Day 15).
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
4. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
5. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
6. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
7. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
10. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 ... audience, has updated the incredibly successful Serialisation Countdown calendar ... interactive PDF, available at pharmaserialisation.com shows the ... which they will be coming into force. ... longer a matter of "if", but "when" they will ...
(Date:9/18/2014)... 2014  A $3 million grant from The Glenn ... Michigan to establish a national center of excellence in ... Aging Research at U-M will focus on exploiting and ... effects of aging and postpone diseases in animal models. ... help develop medications that may help people live longer, ...
(Date:9/18/2014)... PLAINSBORO, N.J. , Sept. 18, 2014 ... the National Hemophilia Foundation,s (NHF) new three-year initiative, ... to people with hemophilia and their families/caregivers to ... can impede disease management. The curriculum for the ... Your Provider About Pain , focuses on improving ...
Breaking Medicine Technology:Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
... TARRYTOWN, N.Y., Nov. 2, 2011 Siemens Healthcare Diagnostics ... a partnership aimed at setting new standards in ... of patients, infectious disease states and potential treatment paths. ... make existing Siemens molecular HIV tests compatible with the recently ...
... world leader in diabetes care, announced today that it has ... (DHF), a non-profit organization that raises diabetes awareness and connects ... of the Drive the Switch program, which has motivated more ... and their doctor about options for insulin delivery, like the ...
Cached Medicine Technology:New Siemens - Illumina Partnership Targets Clinical Infectious Disease Testing Using Next-Generation Sequencing 2New Siemens - Illumina Partnership Targets Clinical Infectious Disease Testing Using Next-Generation Sequencing 3Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 2Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 3Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 4Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 5Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 6Novo Nordisk Donates $50,000 to Diabetes Hands Foundation in Recognition of the Drive the Switch Program's Inaugural Year 7
(Date:9/18/2014)... expect to pay higher employee contributions for their health ... officers about the impact of the Patient Protection and ... conducted by the Darla Moore School of Business at ... Patrick Wright, a professor in strategic human resource management, ... Officers. The survey is distributed to more than 560 ...
(Date:9/18/2014)... guidelines recommending that elderly men should not be routinely ... according to a new study led by researchers at ... letter online in JAMA Internal Medicine , focused ... to test for prostate cancer., "We found that the ... of elderly men in particular has been minimal at ...
(Date:9/18/2014)... For years, neuroscientists have been trying to develop tools ... circuitry in actionfrom the first moment a neuron fires ... get this complete picture, neuroscientists are working to develop ... Researchers at Caltech have developed one such tool that ... a living organism. , The worka collaboration between Viviana ...
(Date:9/18/2014)... With the swift industrial development of ... as smart phones, tablets and PDAs, a complete change ... devices are viewed these days. From only being used ... a mode for creating and delivering content while on ... , The complete makeover of this (mobile) ...
(Date:9/18/2014)... Technology Association of Georgia in collaboration ... TAG Social Savvy Awards this week at a special ... Center in Downtown Atlanta. The event celebrates Georgia’s best ... was honored with the 2014 TAG Social Savvy People’s ... innovators in 6 other award categories: , ...
Breaking Medicine News(10 mins):Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Sensing neuronal activity with light 2Health News:Sensing neuronal activity with light 3Health News:Sensing neuronal activity with light 4Health News:Sensing neuronal activity with light 5Health News:Transparency Market Research: M-health Market Study 2018 2Health News:Transparency Market Research: M-health Market Study 2018 3Health News:Transparency Market Research: M-health Market Study 2018 4Health News:Winners Honored at 2014 TAG Social Savvy Awards 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 3
... the market , WEDNESDAY, Oct. 14 (HealthDay News) -- Peter ... Management and Budget, is reported to drink so much tea, ... see if his body could metabolize his voluminous intake of ... suited to the task, and Orszag can easily go about ...
... Calif., Oct. 14 Bionovo, Inc. (Nasdaq: BNVI ) ... Medicine and Co-Director of the Women,s Cancer Program at the ... Tripathy is a world renowned leader and researcher in the ... have one of the world,s foremost authorities in the area ...
... ... Group ,as key part of innovative quit smoking program , ... Auckland, New Zealand (Vocus) October 14, 2009 ... Health, has recently marked one year of successful operation with HSAGlobal,s STOMP text message-based ...
... , ... people who suffer from sleeping problems report better sleep with Gene-Eden, a natural supplement that ... ... with users of the natural antiviral Gene-Eden. Analysis of the interviews revealed that the users ...
... (NYSE: CNO ) announced today that, in compliance with ... access to information, it will post certain important information on ... The materials consist of a Current Report on Form ... Securities Exchange Commission (the "SEC") after 5:30 p.m. on Tuesday, ...
... , PORTLAND, Ore., Oct. 13 The following is ... of Regence BlueCross BlueShield, regarding the Senate Finance Committee vote ... , "Regence continues to be cautiously optimistic that an economically ... Today,s vote is an important step toward ensuring long-term ...
Cached Medicine News:Health News:Are Commercial Genetic Tests Worth Taking? 2Health News:Are Commercial Genetic Tests Worth Taking? 3Health News:Bionovo Adds Dr. Debu Tripathy to Their Medical Advisory Board 2Health News:Bionovo Adds Dr. Debu Tripathy to Their Medical Advisory Board 3Health News:First Commercial Text Messaging Smoking Cessation Service Marks One Year of Operation 2Health News:First Commercial Text Messaging Smoking Cessation Service Marks One Year of Operation 3Health News:Users of Gene-Eden, a Natural Antiviral, Report less Sleeping Problems in a Recent Study 2Health News:Users of Gene-Eden, a Natural Antiviral, Report less Sleeping Problems in a Recent Study 3Health News:Conseco Announces Availability of Important Information on its Website 2
Fundamental help with all major urologic conditions and diseases, plus time-saving recommendations on important problems....
This easy-to-navigate reference provides clear, current, clinically proven recommendations for diagnosis and treatment of neurologic disorders....
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
... eText is a concise yet complete ... recommendations for cardiovascular disease. In addition ... electronic textbook, a full desktop version ... In addition to the electronic textbook, ...
Medicine Products: